ISNES, Belgium, Sept. 26 2018 /PRNewswire/ — VolitionRx Limited (NYSE American: VNRX) (“Volition”) today released a video featuring members of its Scientific Advisory Board (SAB). The video was taken at Volition’s laboratories in Belgium during the last SAB meeting and features members of the SAB discussing their involvement with Volition and support of its mission to significantly improve cancer diagnostics.
The SAB is a multi-disciplinary international board with expertise in broad areas of technology and convenes at least twice a year to give high level advice and counsel to Volition’s scientific team. Chaired by Dr. Alan Colman, the Board has seven other members, all highly-respected leading experts in their individual fields.
Dr. Colman commented “The role of the SAB is to review and advise the Volition team on the development of its scientific program. Every member provides invaluable insight and input which helps drive scientific rigour.”
 
About Volition
Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. The company’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as it focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition’s website https://volitionrx.com/ or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Nucleosomics® is a trademark of VolitionRx Limited and its subsidiaries.
Media/Investor Contacts
Louise Day, Chief Marketing & Communications Officer
mediarelations@volitionrx.com
+44 (0)7557 774620
Scott Powell, Executive Vice President, Investor Relations
investorrelations@volitionrx.com
+1 (646) 650 1351
Joseph Green, Edison Advisors
jgreen@edisongroup.com
+1 (646) 653 7030
